Biomarkers in Psychiatry

Biomarker Basics - Defining the Dots

• Definition: An objective, quantifiable biological characteristic measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.
• Key Types:
  • Diagnostic: Aid in confirming/classifying disorders (e.g., CSF Aβ42/tau for Alzheimer's, though not primary for psychiatric Dx).
  • Prognostic: Predict future disease course/outcome (e.g., inflammatory markers in depression).
  • Predictive: Identify likelihood of response to a specific treatment (e.g., genetic markers for antidepressant response).
  • Pharmacodynamic/Monitoring: Measure drug effect on target or disease activity (e.g., drug levels, receptor occupancy).
  • Susceptibility/Risk: Indicate predisposition to a disorder (e.g., APOE ε4 allele for Alzheimer's, some genetic risk scores for schizophrenia).
• Ideal Characteristics: High sensitivity & specificity, reliable, reproducible, non-invasive, cost-effective, clinically relevant, easy to measure, reflects pathophysiology.
• Challenges in Psychiatry:
  • Heterogeneity of disorders (many underlying causes for similar symptoms).
  • Symptom overlap across different diagnoses.
  • Complex, multifactorial pathophysiology.
  • Ethical considerations (e.g., genetic screening).

⭐ Currently, no single biomarker is sufficient for diagnosing major psychiatric disorders; diagnosis remains primarily clinical, based on symptom criteria. This is a crucial point for exams, highlighting the limitations despite ongoing research.

Brain Insights - Imaging & Electrical

Neuroimaging Techniques:

• EEG (Electroencephalography):
  • Records spontaneous cortical electrical activity.
  • Uses: Seizures, sleep disorders, delirium.
  • qEEG: Potential biomarkers in depression, ADHD (altered power spectra).
• ERPs (Event-Related Potentials):
  • Time-locked EEG responses to events.
  • Key components:
    • P300: ↓ amplitude in schizophrenia, dementia (attention, context updating).
    • MMN: ↓ amplitude in schizophrenia (auditory change detection).

⭐ Reduced P300 amplitude in ERPs is a consistent finding in schizophrenia, reflecting deficits in attention and information processing.

Molecular Clues - Genes, 'Flames & Fluids

• Genetic Markers:
  • Polygenic Risk Scores (PRS): Aggregate small effects of many DNA variants (SNPs).
  • Key Candidate Genes: BDNF (Brain-Derived Neurotrophic Factor), COMT (Catechol-O-Methyltransferase), SLC6A4 (5-HTTLPR for serotonin transporter).
  • Epigenetics: DNA methylation, histone modifications altering gene activity without DNA sequence change.
• Inflammatory Markers ('Flames):
  • Pro-inflammatory Cytokines: ↑ Interleukin-6 (IL-6), ↑ Tumor Necrosis Factor-alpha (TNF-α).
  • C-Reactive Protein (CRP): Acute phase reactant, often elevated in mood/psychotic disorders.
  • Microglial activation & Kynurenine pathway dysregulation contributing to neuroinflammation.
• Neurochemical & Fluid Markers ('Fluids):
  • CSF Metabolites: ↓ Homovanillic acid (HVA - dopamine), ↓ 5-Hydroxyindoleacetic acid (5-HIAA - serotonin).
  • Peripheral: Salivary/urinary cortisol (HPA axis activity), plasma BDNF levels.
  • 📌 Mnemonic: Genes, Inflammation, Neurotransmitters (GIN) for molecular clues.

⭐ Reduced brain-derived neurotrophic factor (BDNF) levels are consistently implicated in Major Depressive Disorder and influence antidepressant treatment response.

Clinical Utility - Bench to Bedside

• Current Applications:
  • Diagnosis: Aid differential diagnosis (e.g., rule out organic causes); not standalone.
  • Prognosis: Emerging for predicting illness course or treatment response.
  • Treatment Selection: Pharmacogenomics (e.g., CYP2D6, CYP2C19 variants) guides antidepressant choice, ↓ side effects.
• Limitations:
  • Low specificity/sensitivity for most disorders.
  • Disease heterogeneity; research replication issues.
  • Cost, accessibility.
• Ethical Aspects:
  • Stigmatization, genetic determinism.
  • Data privacy, informed consent.
• Future Outlook:
  • Multi-modal biomarkers (genomics, imaging, EEG).
  • AI/ML for personalized psychiatry.

  ⭐ Pharmacogenomic tests (e.g., for CYP2D6, CYP2C19) help tailor antidepressant therapy by predicting drug metabolism, potentially improving efficacy and reducing adverse events.

High‑Yield Points - ⚡ Biggest Takeaways

• No definitive diagnostic biomarkers exist for most psychiatric illnesses yet.
• Key research areas: genetic markers (e.g., APOE ε4 for Alzheimer's), neuroimaging, and CSF analysis.
• ↓ CSF 5-HIAA (serotonin metabolite) is associated with suicidality and impulsivity.
• Structural neuroimaging (MRI, CT) primarily rules out organic pathology.
• Functional neuroimaging (fMRI, PET) shows altered brain activity patterns but is mainly a research tool.
• Pharmacogenomics (e.g., HLA-B*1502 for carbamazepine risk) helps predict drug response/adverse effects.